Phospholipid remodeling and its derivatives are associated with COVID-19 severity - 04/05/23
, Xiaojun Xiao, PhD b, ⁎ , Shau-Ku Huang, PhD b, f, g, ⁎
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Graphical abstract |
Abstract |
Background |
Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.
Objective |
We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.
Methods |
We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.
Results |
Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.
Conclusion |
Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19’s severity and pathogenesis.
Il testo completo di questo articolo è disponibile in PDF.Key words : COVID-19, lipidomics, phospholipid ratio, LPC 16:1, LPE 18:1
Abbreviations used : APACHE II, AUC, COVID-19, FDR, LPC 16:1, LPC, LPE 18:1, LPE, PC O-, PC, PE O-, PE, SARS-CoV-2
Mappa
| The first 3 authors contributed equally to this article and all should be considered first author. |
|
| Supported by the National Natural Science Foundation of China (grants 22106108, U1801286, 31770984, 81901634), the Natural Science Foundation of Guangdong Province (2019A1515110407), the Shenzhen Science and Technology Peacock Team Project (KQTD20170331145453160), the China Postdoctoral Science Foundation (2021M690785), the Key Science and Technology Project of Shenzhen (JSGG20200225153031960), and the Retired Experts Program of Guangdong Province (2020A1313030065). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 151 - N° 5
P. 1259-1268 - Maggio 2023 Ritorno al numero
Articolo precedente
- Asthma and carotid artery plaques
- Juan Carlos Cardet, Natalia Weare-Regales, Richard F. Lockey
- Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation
- Ayobami T. Akenroye, Jodi B. Segal, Guohai Zhou, Dinah Foer, Lily Li, G. Caleb Alexander, Corinne A. Keet, John W. Jackson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.